Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNASDAQ:LIVNNASDAQ:NVCRNASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$31.61-2.3%$34.73$29.32▼$51.00$1.81B1.79786,005 shs692,977 shsLIVNLivaNova$41.88-3.0%$38.77$32.48▼$61.94$2.35B0.84650,163 shs602,740 shsNVCRNovoCure$18.54+2.4%$17.53$14.17▼$34.13$2.02B0.731.14 million shs869,910 shsRXSTRxSight$15.68-1.3%$17.11$12.53▼$62.88$637.19M1.32687,803 shs670,247 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis-2.30%-12.44%-6.53%-26.08%-38.07%LIVNLivaNova-3.01%-5.68%+15.28%-11.72%-30.86%NVCRNovoCure+2.37%+3.63%+4.74%-16.07%-21.77%RXSTRxSight-1.32%+10.50%+8.36%-47.03%-74.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis3.1099 of 5 stars3.42.00.00.03.71.71.9LIVNLivaNova3.7779 of 5 stars4.53.00.00.03.51.71.3NVCRNovoCure3.5937 of 5 stars3.31.00.04.53.61.70.0RXSTRxSight2.969 of 5 stars4.21.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.80Moderate Buy$58.0083.48% UpsideLIVNLivaNova 3.00Buy$59.2941.56% UpsideNVCRNovoCure 2.67Moderate Buy$32.8377.09% UpsideRXSTRxSight 2.30Hold$37.90141.71% UpsideCurrent Analyst Ratings BreakdownLatest RXST, LIVN, ENOV, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025LIVNLivaNovaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$60.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/13/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.005/8/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $55.005/8/2025LIVNLivaNovaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $61.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.15B0.84$4.61 per share6.86$62.66 per share0.50LIVNLivaNova$1.28B1.79$3.76 per share11.15$23.72 per share1.77NVCRNovoCure$621.71M3.32N/AN/A$3.39 per share5.47RXSTRxSight$148.31M4.30N/AN/A$4.47 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$33.26M-$13.95N/A9.91N/A-5.95%4.39%2.80%8/6/2025 (Estimated)LIVNLivaNova$17.55M-$4.0999.7113.34N/A1.91%13.81%7.07%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)Latest RXST, LIVN, ENOV, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/26/2025Q4 2024ENOVEnovis$0.92$0.98+$0.06-$12.05$555.14 million$560.98 million2/25/2025Q4 2024RXSTRxSight$0.10-$0.15-$0.25-$0.15$40.23 million$40.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.402.271.12LIVNLivaNova0.463.372.87NVCRNovoCure0.271.491.44RXSTRxSightN/A12.6711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%LIVNLivaNova97.64%NVCRNovoCure84.61%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.70%LIVNLivaNova0.29%NVCRNovoCure6.29%RXSTRxSight9.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis6,80057.12 million55.49 millionOptionableLIVNLivaNova2,90054.53 million54.15 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableRXST, LIVN, ENOV, and NVCR HeadlinesRecent News About These CompaniesRxSight, Inc. (NASDAQ:RXST) Receives $37.90 Average PT from AnalystsMay 24 at 3:33 AM | americanbankingnews.comDo Options Traders Know Something About RxSight Stock We Don't?May 23 at 10:53 AM | msn.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Hold" by BrokeragesMay 23 at 1:31 AM | marketbeat.comSilvercrest Asset Management Group LLC Invests $2.99 Million in RxSight, Inc. (NASDAQ:RXST)May 22 at 4:57 AM | marketbeat.comRxSight (NASDAQ:RXST) Upgraded to Overweight at Wells Fargo & CompanyMay 21 at 8:15 AM | marketbeat.comPoint72 Asset Management L.P. Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 21 at 5:20 AM | marketbeat.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comPolar Asset Management Partners Inc. Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Purchases 39,347 Shares of RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Purchased by Lazard Asset Management LLCMay 17, 2025 | marketbeat.comEnsign Peak Advisors Inc Purchases 27,913 Shares of RxSight, Inc. (NASDAQ:RXST)May 17, 2025 | marketbeat.comBalyasny Asset Management L.P. Takes $824,000 Position in RxSight, Inc. (NASDAQ:RXST)May 17, 2025 | marketbeat.comPanoramic Capital LLC Makes New $761,000 Investment in RxSight, Inc. (NASDAQ:RXST)May 16, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comNo Street GP LP Increases Stock Position in RxSight, Inc. (NASDAQ:RXST)May 16, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 23,863 Shares of RxSight, Inc. (NASDAQ:RXST)May 16, 2025 | marketbeat.comBank of America Corp DE Acquires 413,737 Shares of RxSight, Inc. (NASDAQ:RXST)May 15, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 15, 2025 | marketbeat.comVoya Investment Management LLC Sells 70,274 Shares of RxSight, Inc. (NASDAQ:RXST)May 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?RXST, LIVN, ENOV, and NVCR Company DescriptionsEnovis NYSE:ENOV$31.61 -0.76 (-2.34%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$31.56 -0.06 (-0.18%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LivaNova NASDAQ:LIVN$41.88 -1.30 (-3.01%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$43.46 +1.58 (+3.78%) As of 05/23/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$18.54 +0.43 (+2.37%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.48 -0.05 (-0.30%) As of 05/23/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.RxSight NASDAQ:RXST$15.68 -0.21 (-1.32%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$15.68 +0.01 (+0.03%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
